464 related articles for article (PubMed ID: 20854338)
1. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.
Gray TR; Choo RE; Concheiro M; Williams E; Elko A; Jansson LM; Jones HE; Huestis MA
Addiction; 2010 Dec; 105(12):2151-9. PubMed ID: 20854338
[TBL] [Abstract][Full Text] [Related]
2. Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes.
de Castro A; Jones HE; Johnson RE; Gray TR; Shakleya DM; Huestis MA
Ther Drug Monit; 2011 Aug; 33(4):443-52. PubMed ID: 21743375
[TBL] [Abstract][Full Text] [Related]
3. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.
de Castro A; Jones HE; Johnson RE; Gray TR; Shakleya DM; Huestis MA
Clin Chem; 2011 Mar; 57(3):449-58. PubMed ID: 21245372
[TBL] [Abstract][Full Text] [Related]
4. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
Kaltenbach K; Holbrook AM; Coyle MG; Heil SH; Salisbury AL; Stine SM; Martin PR; Jones HE
Addiction; 2012 Nov; 107 Suppl 1(0 1):45-52. PubMed ID: 23106926
[TBL] [Abstract][Full Text] [Related]
5. Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.
Himes SK; Goodwin RS; Rock CM; Jones HE; Johnson RE; Wilkins DG; Huestis MA
Ther Drug Monit; 2012 Jun; 34(3):337-44. PubMed ID: 22495425
[TBL] [Abstract][Full Text] [Related]
6. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy.
Liu AJ; Jones MP; Murray H; Cook CM; Nanan R
Aust N Z J Obstet Gynaecol; 2010 Jun; 50(3):253-8. PubMed ID: 20618243
[TBL] [Abstract][Full Text] [Related]
7. The relationship between gestational age and the severity of neonatal abstinence syndrome.
Gibson KS; Stark S; Kumar D; Bailit JL
Addiction; 2017 Apr; 112(4):711-716. PubMed ID: 27886650
[TBL] [Abstract][Full Text] [Related]
8. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study.
Desai RJ; Huybrechts KF; Hernandez-Diaz S; Mogun H; Patorno E; Kaltenbach K; Kerzner LS; Bateman BT
BMJ; 2015 May; 350():h2102. PubMed ID: 25975601
[TBL] [Abstract][Full Text] [Related]
9. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.
Kacinko SL; Jones HE; Johnson RE; Choo RE; Huestis MA
Clin Pharmacol Ther; 2008 Nov; 84(5):604-12. PubMed ID: 18701886
[TBL] [Abstract][Full Text] [Related]
10. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
Nechanská B; Mravčík V; Skurtveit S; Lund IO; Gabrhelík R; Engeland A; Handal M
Addiction; 2018 Jul; 113(7):1286-1294. PubMed ID: 29443414
[TBL] [Abstract][Full Text] [Related]
11. Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
Pizarro D; Habli M; Grier M; Bombrys A; Sibai B; Livingston J
J Subst Abuse Treat; 2011 Apr; 40(3):295-8. PubMed ID: 21255960
[TBL] [Abstract][Full Text] [Related]
12. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study.
Bakstad B; Sarfi M; Welle-Strand GK; Ravndal E
Eur Addict Res; 2009; 15(3):128-34. PubMed ID: 19332991
[TBL] [Abstract][Full Text] [Related]
13. Bioanalysis for cocaine, opiates, methadone, and amphetamines exposure detection during pregnancy.
Concheiro M; Lendoiro E; de Castro A; Gónzalez-Colmenero E; Concheiro-Guisan A; Peñas-Silva P; Macias-Cortiña M; Cruz-Landeira A; López-Rivadulla M
Drug Test Anal; 2017 Jun; 9(6):898-904. PubMed ID: 27595432
[TBL] [Abstract][Full Text] [Related]
14. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.
Metz V; Jagsch R; Ebner N; Würzl J; Pribasnig A; Aschauer C; Fischer G
Hum Psychopharmacol; 2011 Aug; 26(6):412-21. PubMed ID: 21823171
[TBL] [Abstract][Full Text] [Related]
15. Use of naltrexone in treating opioid use disorder in pregnancy.
Towers CV; Katz E; Weitz B; Visconti K
Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
[TBL] [Abstract][Full Text] [Related]
16. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
Pritham UA; Paul JA; Hayes MJ
J Obstet Gynecol Neonatal Nurs; 2012 Mar; 41(2):180-190. PubMed ID: 22375882
[TBL] [Abstract][Full Text] [Related]
17. The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.
Kreitinger C; Gutierrez H; Hamidovic A; Schmitt C; Sarangarm P; Rayburn WF; Leeman L; Bakhireva LN
J Matern Fetal Neonatal Med; 2016 Mar; 29(5):783-8. PubMed ID: 25758627
[TBL] [Abstract][Full Text] [Related]
18. Methadone and perinatal outcomes: a prospective cohort study.
Cleary BJ; Eogan M; O'Connell MP; Fahey T; Gallagher PJ; Clarke T; White MJ; McDermott C; O'Sullivan A; Carmody D; Gleeson J; Murphy DJ
Addiction; 2012 Aug; 107(8):1482-92. PubMed ID: 22340442
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Kelty E; Hulse G
Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
Unger A; Jagsch R; Jones H; Arria A; Leitich H; Rohrmeister K; Aschauer C; Winklbaur B; Bäwert A; Fischer G
Addiction; 2011 Jul; 106(7):1355-62. PubMed ID: 21438938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
